

## PHARMING TO PARTICIPATE IN DUTCH CONSORTIUM ON BIOMEDICAL MATERIALS

**Leiden, The Netherlands, May 16, 2006.** Biotech company Pharming Group NV (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) announced today its participation in a Dutch consortium on biomedical materials. The BioMedical Materials consortium (BMM) aims to provide a leadership position to the Netherlands in biomedical materials and will facilitate novel product development for various medical applications.

The BMM will use public-private partnerships to fully utilize the strong knowledge base in the Dutch industry and academia on biomedical materials. The other participants in the consortium are Koninklijke DSM N.V., Fortimedix, Fuji-Life Sciences, Innocore, Medtronic, Organon, Philips Research, Pharmacell, Polyganics, De Nierstichting, Radboud Universiteit Nijmegen, Rijksuniversiteit Groningen, Technische Universiteit Eindhoven, TNO, Universiteit Maastricht, Universiteit Twente, and Universiteit Utrecht.

The BMM has a provisional budget of €120 million over five years and is submitting a business plan to the Dutch government to obtain public funding for the consortium. The BMM intends to initiate research activities among participants in the consortium in the third quarter of 2006. In addition, the consortium will utilize potential synergies with other public-private initiatives in the healthcare sector, such as TI Pharma and CTMM. Further details on the BMM consortium are provided on [www.biomedicalmaterialsprogram.nl](http://www.biomedicalmaterialsprogram.nl).

### Background on Pharming Group N.V.

Pharming Group N.V. is developing innovative protein products for unmet needs. The Company’s products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for use in functional foods. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, <http://www.pharming.com>.

*This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.*

---

### Contact:

Carina Hamaker  
Investor Voice  
T: +31 (0)6 537 49959

Sarah MacLeod  
Financial Dynamics  
T: +44 (0)20 7269 7148

Frank Pieper/Samir Singh  
Pharming Group N.V.  
T: +31 (0)71 524 7429